A Study on Subclinical Hypothyroidism in Females Over 50 years of Age by Gopakumar, K S
A STUDY ON SUBCLINICAL HYPOTHYROIDISM IN 
FEMALES  OVER FIFTY YEARS OF AGE  
 
 
 
submitted to 
The Tamil Nadu Dr.M.G.R.Medical University  
 
M.D. DEGREE EXAMINATION 
BRANCH – I (GENERAL MEDICINE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
THE TAMIL NADU DR.M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
 
MARCH 2009
BONAFIDE CERTIFICATE 
 
This is to certify that the dissertation titled “A STUDY ON SUBCLINICAL 
HYPOTHYROIDISM IN FEMALES OVER FIFTY YEARS OF AGE” 
is a bonafide work done by Dr.K.S.GOPAKUMAR, post graduate student, 
Department of General Medicine, Kilpauk Medical College, Chennai-10, 
under my guidance and supervision in partial fulfillment of regulations of  
The Tamilnadu Dr.M.G.R.Medical University for the award of 
M.D.Degree Branch I (General Medicine) during the academic period from 
May 2006 to March 2009. 
 
 
Dr.M.Dhanapal, M.D., D.M., 
 
Director Of Medical Education- OSD and The Dean 
Kilpauk Medical College, 
Chennai – 10. 
 
 
 
 
 
 
 
Prof.G.Rajendran, M.D., 
Professor and Head 
Department of Internal 
Medicine 
Kilpauk Medical College 
Chennai-10 
Prof.B.Chellam, M.D., 
Professor 
Department of Internal 
Medicine 
Kilpauk Medical College 
Chennai-10 
  
ACKNOWLEDGEMENT 
I sincerely thank Prof.D.Dhanapal, M.D., D.M., Dean, Kilpauk Medical 
College, Chennai for permitting me to utilize the facilities needed for this 
dissertation work. 
I am extremely grateful to Prof.Dr.G.Rajendran, M.D., Professor and 
Head of the Department of Internal Medicine, Kilpauk Medical College and 
Hospital for permitting me to carry out this study  and for his constant 
encouragement and guidance. 
I whole heartedly express my sincere thanks to my Chief 
Prof.B.Chellam, M.D Department of  Internal Medicine, Kilpauk Medical 
College for his esteemed guidance and valuable suggestions in all the stages 
of this dissertation. 
I also express my sincere gratitude to Prof.M.D.Selvam, M.D., 
Prof.A.Joseph Navaseelan,M.D., Prof.Chinnayan M.D., 
Prof.D.Varadharajan MD ., for their help and guidance rendered during the 
entire period of my work. 
I wish to thank Dr. S. Rajasekhar MD, Dr.Jayakumar Jayakrishnan 
MD., Assistant Professors, Department of Medicine, Kilpauk Medical College 
for their valuable suggestions and help rendered throughout this work. 
          I also thank my parents, colleagues, friends and staff of our hospital, for 
their support of this work. 
Last but not the least, with sincere gratitude, I thank all the patients 
who contributed so much to this study without whom this study could not 
have been possible. 
 
 
 
 
 
CONTENTS 
 
 
Sl.No. Title Page No. 
1. INTRODUCTION 1 
2. AIM OF THE STUDY 4 
3. REVIEW OF LITERATURE 5 
4. MATERIALS AND METHODS 50 
5. RESULTS  53 
6. DISCUSSION 57 
7. CONCLUSION 60 
 BARS AND CHART  
 PROFOMA  
 MASTER CHART  
 BIBLIOGRAPHY  
 APPENDIX  
 
 
 
 1
                                     INTRODUCTION 
The term subclinical hypothyroidism was originally used to describe the 
patient with a low-normal free T4 but a slightly elevated serum TSH level. 
Other terms for this condition are mild hypothyroidism early thyroid failure, 
preclinical hypothyroidism, and decreased thyroid reserve. The TSH elevation 
in such patients is modest, with values typically between 4 and 15 mU/L, 
although patients with a TSH above 10 mU/L more often have a reduced free 
T4 and may have some hypothyroid symptoms. 
The definition of this syndrome depends significantly on the reference range 
for a normal TSH concentration.  
This syndrome is most often seen in patients with early Hashimoto's disease 
and is a common phenomenon, occurring in 7% to 10% of older women.1,2,3 
Subclinical hypothyroidism may have endogenous causes (chronic 
autoimmune thyroiditis, subacute thyroiditis, postpartum thyroiditis) or 
exogenous causes (thyroidectomy, 131I therapy, antithyroid drugs, inadequate 
thyroid hormone replacement therapy).The prevalence of subclinical 
hypothyroidism is rather high. In the classical population-based study among 
adults in the English county of Whickham the prevalence was 75 per 1000 
women and 28 per 1000 men1; similar figures have been obtained in other 
studies. The higher prevalence of subclinical hypothyroidism in females than 
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in males and in older than in younger subjects is in agreement with the higher 
prevalence of thyroglobulin and thyroid peroxidase (microsomal) antibodies 
in women and in elderly people. 
The natural history of subclinical hypothyroidism is reasonably well known. 
Spontaneous return of increased TSH values into the normal range occurs in 
5.5% after 1. year. 4 Progression to overt hypothyroidism ranges from 7.8% to 
17.8% in various studies. 4,5,6 
Another report indicates that approximately 30% of patients with subclinical 
hypothyroidism had developed overt hypothyroidism after 10 years; the 
higher the initial TSH, the greater the risk . 7 
Clinical manifestation of subclinical hypothyroidism   include abnormal lipid 
metabolism 8,9,10,cardiac dysfunction11,12 and neurologic and mental 
dysfunction13 and several cross-sectional studies have suggested that it confers 
an elevated risk for atherosclerosis and coronary heart  disease.14,15However, 
neither of these associations have been confirmed by others16,17.This 
discrepancy may reflect small size of the study or participation in these study 
limited to one sex. Also, few longitudinal studies have been conducted. The 
relationship between subclincial hypothyroidism and cardiovascular disease is 
therefore controversial and possible outcomes of the conditions remain 
unclear. Importantly several previous studies suggesting that thyroid 
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autoimmunity is a risk factor for coronary heart disease15,18,19 remain 
surrounded by controversies.17,20 
Women with subclincal hypothyroidism didn’t differ from controls with 
regard to BMI, Hypertension and Diabetes Mellitus in previous studies. 14,21 
 
This study has been performed to estimate the prevalence of subclinical 
hypothyroidism and its relation to Hypertension, Diabetes and Ischemic heart 
disease among women above the age of 50 years attending medical out 
patient clinic at Government Kilpauk Medical College and Hospital.     
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AIM OF THE STUDY 
• To estimate the prevalence of subclinical hypothyroidism among 
women above the age of 50 yrs 
 
• To study the relationship of subclinical hypothyroidism to 
Hypertension, Diabetes and Ischemic Heart Disease in those patients 
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 REVIEW OF LITERATURE 
PHYLOGENY, EMBRYOLOGY, AND ONTOGENY 
Phylogeny 
Thyroid tissue is confined to, and is present in, all vertebrates. The 
phylogenetic association of the thyroid gland and the gastrointestinal tract is 
evident in several functions. The salivary and gastric glands, like the thyroid, 
are capable of concentrating iodide in their secretions. 
 
Structural Embryology 
The human thyroid anlage is first recognizable at E 16-17. The primordium 
begins as a thickening of epithelium in the pharyngeal floor. The primitive 
stalk connecting the primordium with the pharyngeal floor elongates into the 
thyroglossal duct , the primordium assumes a bilobate shape, coming into 
contact and fusing with the ventral aspect of the fourth pharyngeal pouch 
when it reaches its final position at about E50. Cells of the lower portion of 
the duct differentiate into thyroid tissue, forming the pyramidal lobe of the 
gland. At this time the lobes contact the ultimobranchial glands, leading to the 
incorporation of C cells into the thyroid. Concomitantly, histologic alterations 
occur throughout the gland, and by 13 to 14 weeks the follicles begin to fill 
with colloid.  
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Functional Ontogeny 
Future follicular cells acquire the capacity to form thyroglobulin (Tg) as early 
as the 29th day of gestation, whereas the capacities to concentrate iodide and 
synthesize thyroxine (T4) are delayed until about the 11th week. As a 
consequence of hypothalamic maturation and increasing secretion of 
thyrotropin-releasing hormone (TRH), the serum TSH concentration increases 
between 18 and 26 weeks. 
 
ANATOMY AND HISTOLOGY 
The thyroid is approximately 15 to 20 g in weight .The normal thyroid is 
made up of two lobes joined by a thin band of tissue, the isthmus. The 
individual lobes normally have a pointed superior pole and a poorly defined 
blunt inferior pole that merges medially with the isthmus.  
Blood supply is by the superior thyroid artery and the inferior thyroid artery. 
Thyroid blood flow range from 4 to 6 mL/min/g. 
The gland is composed of  follicles .Thyroid tissue appears as closely packed 
ring-shaped structures consisting of a single layer of thyroid cells surrounding 
a lumen. The follicular cells are columnar when active and cuboidal when 
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inactive.The thyroid also contains parafollicular cells, or C cells, that are the 
source of calcitonin.  
IODINE AND THE SYNTHESIS AND SECRETION OF THYROID 
HORMONES 
Dietary Iodine 
Formation of normal quantities of thyroid hormone requires the availability of 
adequate quantities of exogenous iodine to allow thyroidal uptake of 
approximately 60 to 75 µg daily, taking into account the fecal losses of about 
10 to 20 µg iodine of iodothyronines as glucuronides and about 100 to 150 µg 
as urinary iodine in iodine-sufficient populations. At least 100 µg of iodine 
per day is required to eliminate all signs of iodine deficiency . Iodine 
deficiency is common in mountainous  regions. 
Iodide Metabolism by the Thyroid Cell 
The process of iodide trapping  is accomplished by a membrane protein, the 
sodium-iodide symporter (NIS or SLC5A). In addition to the active transport 
of iodide from the extracellular fluid, intracellular iodide is also generated by 
the action of the iodotyrosine dehalogenase (Dhal) enzymes. The iodide 
thereby released is immediately reconjugated to newly synthesized 
thyroglobulin after exiting the apical membrane of the cell. 
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Iodide Oxidation and Organification 
Oxidation of iodide and incorporation of the resulting intermediate into the 
hormonally inactive iodotyrosines MIT and DIT is known as organification. 
Oxidation of thyroidal iodide is mediated by the heme-containing protein 
thyroid peroxidase (TPO) and requires the H2O2 generated by the calcium 
dependent Duox1 and 2 enzymes. The rate of organic iodinations is 
dependent on the degree of thyroid stimulation by TSH .  
Iodothyronine Synthesis 
The MIT(mono iodothyronine) and DIT(di iodothyronine) formed via 
oxidation and organic binding of iodide are precursors of the hormonally 
active iodothyronines T4 and T3. Synthesis of T4 from DIT requires the TPO-
catalyzed fusion of two DIT molecules to yield a structure with two 
diiodinated rings linked by an ether bridge (the coupling reaction). Efficient 
synthesis of T4 and T3 in the thyroid requires Tg.  
Storage and Release of Thyroid Hormone 
There are approximately 250 µg T4 per gram of wet weight in normal human 
thyroid. This is sufficient to maintain a euthyroid state for at least 50 days. 
Thyroglobulin is present in the plasma of normal individuals at concentrations 
up to 80 ng/mL. The first step in thyroid hormone release is the endocytosis 
of colloid from the follicular lumen by two processes: macropinocytosis by 
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pseudopods formed at the apical membrane and micropinocytosis by small 
coated vesicles that form at the apical surface. Both processes are stimulated 
by TSH. Following endocytosis, endocytotic vesicles fuse with lysosomes, 
and proteolysis is catalyzed by cathepsin D and D-like thiol proteases, all of 
which are active at the acidic pH of the lysosome.The iodotyrosines released 
from Tg are rapidly deiodinated by an NADPH-dependent iodotyrosine 
deiodinase, and the released iodine is recycled. The thyroid hormone 
transporter MCT8 in the thyroid gland could be involved in the exit of T4 
and/or T3 from the phagolysosome or thyroid cell. Stimulation of D1- and 
D2- (type 1 and 2 deiodinases ) can catalyze 5′-deiodination of T4. T4 release 
from the thyroid cells is inhibited by several agents, the most important of 
which is iodide.  
Role and Mechanism of Thyrotropin (TSH) Effects 
All steps in the formation and release of thyroid hormones are stimulated by 
TSH secreted by the pituitary thyrotrophs . Thyroid cells express the TSH 
receptor (TSHR), a member of the glycoprotein G protein–coupled receptor 
family. Although the TSHR mainly couples to Gs, when activated by high 
concentrations of TSH, it couples also to Gq/11, activating the inositol-
phosphate diacylglycerol cascade. The induction of signal via the 
phospholipase C (PLC) and intracellular Ca2+ pathways regulates iodide 
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efflux, H2O2 production, and Tg iodination while the signal via the protein 
kinase A (PKA) pathways mediated by cAMP regulates iodine uptake and 
transcription of Tg, TPO, and the sodium-iodide symporter (NIS) mRNAs 
leading to thyroid hormone production . The TSHR, in addition to TSH, also 
binds thyroid-stimulating antibody (TSAb), thyroid-blocking antibodies 
(TBAb), and neutral antibodies to the TSHR . 
THYROID HORMONES IN PERIPHERAL TISSUES 
Plasma Transport 
T4 arises solely from direct secretion by the thyroid gland. In normal humans, 
T3 is also released from the thyroid but approximately 80% is derived from 
the peripheral tissues by the enzymatic removal of a single 5′ iodine atom  
from T4. The remaining iodothyronines and their derivatives are generated in 
the peripheral tissues from T4 and T3. Principal among them are 3,3′,5′-
triiodothyronine (reverse T3, or rT3) and 3,3′-diiodo-l-thyronine (3,3′-T2). 
The major iodothyronines are poorly soluble in water and thus bind reversibly 
to plasma proteins. The plasma proteins with which T4 is mainly associated 
are thyroxine-binding globulin (TBG) and transthyretin (TTR) and albumin . 
About 75% to 80% of T3 is bound by TBG, and the remainder by TTR and 
albumin. 
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Thyroxine-Binding Globulin (TBG). 
TBG is a glycoprotein SERPIN family of serine antiproteases of  with a 
molecular mass of about 54 kd. Normal human serum concentration is 270 
nmol/L (1.5 µg/dL). The half-life of the protein in plasma is about 5 days. 
Free Thyroid Hormones 
Because most of the circulating T4 and T3 is bound to TBG, its concentration 
and degree of saturation are the major determinants of the free fraction of T4. 
Binding of the thyroid hormones to the plasma proteins alters their 
metabolism. The negligible urinary excretion of T3 and T4 is due to the 
limited filterability of the hormone-binding protein complexes at the 
glomerulus. The free fraction of T4 (T4/T4 · TBG) is inversely proportional 
to the concentration of unoccupied TBG binding sites.  
Estimates of the free T4 concentration in serum can be generated by direct or 
indirect assays.  It is the free hormone that is available to the tissues for 
intracellular transport and feedback regulation, that induces its metabolic 
effects, and that undergoes deiodination or degradation. The bound hormone 
acts merely as a reservoir. If an increase in TBG occurs, the free T4 
concentration and T3 concentrations can be maintained at normal levels only 
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if the bound hormone increases. The plasma concentration of T4 is 
determined by its rate of entry into, and exit from, the plasma.  
For any level of T4 production, be it increased, normal, or decreased, the total 
plasma T4 level varies inversely with its MCR (Metabolic Clearance Rate). 
Intracellular free T3 and T4 are in equilibrium with the free hormone pool in 
plasma. In the steady-state, the rate of T3 and T4 metabolism is rate-limiting 
in the exit of hormones from the plasma. 
T4 and T3 Transport across Cell Membranes and Intracellular T3 Binding 
MCT8 is a T-type amino acid transporter belonging to the monocarboxylate 
transporter family and facilitates transport of T3, T4, rT3  across cell 
membranes in vitro. 
Iodothyronine Deiodination 
The most important pathway for T4 metabolism is its outer ring (5′) 
monodeiodination to the active thyroid hormone, T3. This reaction is 
catalyzed by the type 1 and 2 deiodinases (D1 and D2) and is the source of 
more than 80% of the circulating T3. Inner ring deiodination, an inactivating 
step, is catalyzed primarily by the type 3 (D3) deiodinase, which inactivates 
T3 and prevents activation of T4 by converting it to reverse T3. The 
structures of the three deiodinases are similar, and contain the amino acid 
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selenocysteine in the active catalytic center . Selenium is thought to be the 
iodine acceptor during deiodination reactions. 
 
Quantitative and Qualitative Aspects of Thyroid Hormone Metabolism 
Thyroid Hormone Turnover 
In the normal adult, T4 has a distribution volume of approximately 10 L . 
Because the concentration of total T4 in plasma is approximately 100nmol/L 
(8µg/dL), the extrathyroidal T4 pool is approximately 1mmol (800µg). In the 
adult, the fractional rate of turnover of T4 in the periphery is about 10% per 
day (halflife, 6.7 days). Thus, about 1.1 L of the peripheral T4 distribution 
space is cleared of hormone daily, a volume containing approximately 110 
nmol (85 µg) of T4. 
The kinetics of T3 metabolism differ from those of T4, partly because of its 
10- to 15-fold lower affinity for TBG. The volume of distribution of T3 in the 
normal adult is about 40 L. At a mean normal serum T3 concentration of 
1.8nmol/L (120ng/dL), the daily production of T3 is approximately 50 nmol 
(33µg).The rapid metabolic clearance rate of the product of inner ring T4 
deiodination, and the low concentration in plasma (0.25nmol/L, 15ng/dL) 
combine to yield daily production rates for rT3 of about 45nmol. 80% -85% 
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of T3 and all of rT3 production can be accounted for by peripheral 
deiodination of T4.  
Mechanism of Thyroid Hormone Action 
Thyroid hormone acts by binding to a specific nuclear thyroid hormone 
receptor (TR), which, in turn, binds to DNA usually as a heterodimer with 
retinoid X receptor at specific sequences (thyroid hormone response elements, 
or TREs) dictated by the DNA binding-site preferences of the RXR-TR  
complex .Triiodothyronine has a 15-fold higher binding affinity for TRs than 
does T4, explaining its function as the active thyroid hormone. In humans, 
there are two TR genes, α and β, found on different chromosomes (TRα, 
chromosome 17; TRβ, chromosome 3). There are several alternatively spliced 
gene products from each of these genes forming both active and inactive gene 
products. The active proteins are TRα1, and TRs β1, β2, and β3. 
REGULATION OF THYROID FUNCTION 
The Hypothalamic-Pituitary-Thyroid Axis 
The thyroid participates with the hypothalamus and pituitary in a classical 
feedback control loop . In addition, there is an inverse relationship between 
the glandular organic iodine level and the rate of hormone formation. 
Autoregulatory mechanisms within the gland, in turn, tend to maintain a 
constant thyroid hormone pool. Finally, the hypothalamic-pituitary feedback 
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mechanism senses variations in the availability of free thyroid hormones, 
however small, and acts to correct them. There is a close relationship between 
the hypothalamus, the anterior pituitary, the thyroid gland, and still higher 
centers in the brain, the function of the entire complex being modified in a 
typical negative-feedback manner by the availability of the thyroid hormones. 
Thyrotropin-Releasing Hormone (TRH) Synthesis and Secretion 
TRH, a modified tripeptide (pyroglutamyl-histidyl-proline-amide), is derived 
from a large prepro-TRH molecule. The parvocellular region of the 
paraventricular nuclei (PVN) of the hypothalamus is the source of the TRH 
that regulates TSH secretion. TRH travels in the axons of the peptidergic 
neurons through the median eminence and is released close to the 
hypothalamic-pituitary portal plexus. T3 suppresses the levels of prepro-TRH 
mRNA in the hypothalamus, but normal feedback regulation of prepro-TRH 
mRNA synthesis by thyroid hormone requires a combination of T3 and T4 in 
the circulation. In addition to inhibiting the synthesis of prepro-TRH mRNA, 
thyroid hormone also blocks the capacity of TRH to stimulate TSH release 
from the thyrotroph. 
Thyrotropin (Thyroid-Stimulating Hormone) Synthesis and Secretion 
It is a glycoprotein secreted by the thyrotrophs in the anteromedial portion of 
the adenohypophysis. TSH is composed of an α-subunit of 14 kd (92 amino 
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acids) and a specific β-subunit synthesized in thyrotrophs, which is a 112-
amino-acid protein. The quantity of β-subunit is rate-limiting for TSH 
secretion. TRH increases and thyroid hormone suppresses the transcription of 
both subunits. 
In normal serum, TSH is present at concentrations between 0.4 and 4.2 mU/L. 
The level is increased in primary hypothyroidism and reduced in 
thyrotoxicosis. The plasma TSH half-life is about 30 minutes, and production 
rates in humans are 40 to 150 mU/day. Circulating TSH displays both 
pulsatile and circadian variations. Both T4 and T3 mediate the feedback 
regulation of TSH secretion, and TRH determines its set-point. There is a 
linear inverse relationship between the serum free T4 concentration and the 
log of the TSH, making the serum TSH concentration an exquisitely sensitive 
indicator of the thyroid state of patients with an intact hypothalamic-pituitary 
axis. 
Somatostatin decreases TSH secretion in vitro and in vivo, but prolonged 
treatment with a somatostatin analogue does not cause hypothyroidism. 
Dopamine is a regulator of TSH secretion, but chronic administration of 
dopamine agonists do not cause central hypothyroidism, indicating that 
compensatory mechanisms negate these acute effects. Glucocorticoids  in 
high doses transiently suppress TSH secretion, although prolonged therapy is 
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not associated with central hypothyroidism. Bexarotene, a retinoid X receptor 
agonist used for treatment of T-cell lymphoma, suppresses TSH sufficiently 
to cause central hypothyroidism, presumably by reducing TSH-β gene 
transcription. 
Iodine Deficiency 
In humans compensatory alterations in thyroid function come into operation 
when total iodine intake falls below 75 µg/d. 
Effects of Increased Iodine Intake on Thyroid Hormone Synthesis 
The quantity of iodine organified in thyroglobulin which includes T4 and T3 
displays a biphasic response to increasing doses of iodide, at first increasing 
and then decreasing as a result of a relative blockade of organic binding. This 
decreasing yield of organic iodine from increasing doses of iodide, termed the 
Wolff-Chaikoff effect, results from a high concentration of inorganic iodide 
within the thyroid cell. The mechanism for organification inhibition may 
involve inhibitory effects of high iodide concentrations on TPO and THOX2. 
Effects on Thyroid Hormone Release 
An important practical effect of pharmacologic doses of iodine is the prompt 
inhibition of thyroid hormone release. The mechanism is unknown, but the 
effect is mediated at the thyroid cell level, rather than through an action on 
TSH.  
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Aging and the Thyroid 
In the healthy elderly patient, there is a normal free T4 but a relatively lower 
serum TSH than in younger individuals. The requirement for complete 
levothyroxine replacement is reduced about 20% by the eighth decade. 
LABORATORY ASSESSMENT OF THYROID STATUS 
Tests of the Hypothalamic-Pituitary-Thyroid Axis 
The rate of TSH secretion is exquisitely sensitive to the plasma concentrations 
of free thyroid hormones.  The normal range of the serum TSH concentration 
by immunometric assay varies slightly in different laboratories but is most 
commonly 0.4 to 4.2mU/L. The free α-subunit common to TSH, FSH, LH, 
and hCG is generally detectable in serum with a normal range of 1 to 5µg/L, 
but the TSH β-subunit is not.  
TSH in Patients with Thyroid Dysfunction 
Patients with hyperthyroidism (excess thyroid hormone secretion) and/or 
thyrotoxicosis (excess thyroid hormone from any cause) will virtually always 
have a subnormal TSH. Patients with hypothalamic or pituitary 
hypothyroidism often have normal or even slightly elevated serum TSH. The 
circulating TSH generally has reduced biologic activity due to abnormal 
glycosylation, reflecting the impaired access of TRH to the thyrotroph. In 
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general, the degree of TSH elevation correlates with the clinical severity of 
the hypothyroidism. Patients with serum TSH values in the range of 5 to 15 
mU/L have few if any symptoms23, and the serum free T4 is typically low-
normal while serum free T3 concentrations are normal. 22 24  Such individuals 
with modest TSH elevation are said to have subclinical hypothyroidism if the 
serum free T4 is in the normal range. An elevation in both serum TSH and 
free T4 is unusual and indicates either autonomous TSH production as with a 
TSH-secreting pituitary tumor, resistance to thyroid hormone (RTH), or 
hyperthyroidism with an artifactual elevation in TSH.  
 
 
QUANTITATION OF SERUM THYROID HORMONE 
CONCENTRATIONS 
Total T4 and T3 
The normal range for total T4 is 64 to 142 nmol/L (5 to 11 µg/dL). Normal 
serum T3 concentrations are 1.1 to 2.9 nmol/L (70 to 190 ng/dL). 
Concentrations of Free T4 and T3. 
The absolute concentration of free hormone is the product of the total 
hormone concentration and the fraction that is dialyzable or ultrafiltrable . 
About 0.02% of T4 and 0.3% of T3 is free or unbound . The normal ranges 
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for free T4 and T3 are 9 to 30 pmol/L (0.7 to 2.5 ng/dL) and for free T3, 3 to 
8 pmol/L (0.2 to 0.5 ng/dL). 
There are two general categories of methods for estimating free thyroid 
hormones: Comparative free T4 methods and so-called free T4 index 
methods. Three general approaches are used: (1) two-step labeled hormone 
methods, (2) one-step labeled analogue methods, and (3) labeled antibody 
approaches .In general, two-step labeled hormone back titration methods are 
less subject to artifacts due to abnormal binding proteins, changes in albumin, 
TBG, or increases in free fatty acids than are one-step hormone analogue 
methods.25 26 28 All general approaches are subject to artifacts from 
endogenous antibodies to T4, abnormal binding proteins, or illness. 27 29 
The Free T4Index (FT4I). 
Particularly useful in estimating the free T4 in severely ill patients is the 
determination of the thyroid hormone–binding ratio (THBR), multiplying this 
result by the total T4 (or T3) to obtain a free hormone index (FT4I or FT3I). 
Causes of a Suppressed TSH. 
The most common cause of a reduction in serum TSH is an excess supply of 
thyroid hormone due to either increased endogenous thyroid hormone 
production or excessive exogenous thyroid hormone. Because the 
concentration of TSH is inversely proportional to the degree of thyroid 
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hormone excess, patients with clinical symptoms almost invariably have 
serum TSH concentrations below 0.1 mU/L. Such patients nearly always have 
an increase in the serum free T4. The hypothalamic-pituitary axis may remain 
suppressed for up to 3 months after complete resolution of the thyrotoxic 
state. 30 31 The best test for assessing the physiologic state in such patients is 
the free T4 or FT4I. In severe illnesses, with or without dopamine infusion or 
excess glucocorticoid, TSH is suppressed, making assessment of thyroid 
functional status difficult . Because the FT4I may also be reduced in such 
patients, astute clinical judgment is required to assign thyroid status. 
 
Causes of an Elevated TSH 
Elevations in TSH nearly always imply a reduction in the supply of T4 or T3, 
which may be permanent or transient. Primary hypothyroidism is far and 
away the usual explanation. Other causes include acutely ill patients as in 
renal insufficiency32 or the asynchronous return of the hypothalamic-pituitary 
and thyroid axes to normal as critically ill patients recover. 33 Iodine 
deficiency is the most common cause of an elevation in TSH worldwide. 
Patients with hypothalamic-pituitary dysfunction may have clinical and 
chemical hypothyroidism, but low, normal, or even elevated serum TSH 
concentrations. The explanation for this paradox is that the biologic 
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effectiveness of the circulating TSH is impaired due to abnormal 
glycosylation secondary to reduced TRH stimulation of the thyrotrophs.  
In adrenal insufficiency, TSH may be modestly elevated but returns to normal 
with glucocorticoid replacement 
 
Tests That Assess the Metabolic Impact of Thyroid Hormones 
Basal Metabolic Rate 
Basal metabolic rate (BMR) measures oxygen consumption under specified 
conditions of fasting, rest, and tranquil surroundings. Under these conditions, 
the energy equivalent of 1 L of oxygen is 4.83 kcal. Values in patients, 
calculated as a percentage of established normal means for gender and age, 
normally range from -15% to +5%. In severely hypothyroid patients, values 
may be as low as -40%, and in thyrotoxic patients, these may reach +25% to 
+50%. 
Biochemical Markers of Altered Thyroid Status 
Occasionally markedly elevated creatine kinase MM isoenzyme or low-
density lipoprotein (LDL) cholesterol lead to the recognition of 
hypothyroidism. 
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Serum Thyroglobulin 
The mean normal values vary with the assay used but are on the order of 30 
pmol/L (20 ng/mL). Values are elevated in both endemic and sporadic 
nontoxic goiter, and the degree of elevation correlates with the thyroid size.  
Tests for Thyroid Autoantibodies 
Autoantibodies to Thyroid Peroxidase and Thyroglobulin 
Tg and TPO autoantibodies appear to be a secondary response to thyroid 
injury and are not thought to cause disease themselves.TPOAb autoantibodies 
correlate with thyroidal damage and lymphocytic infiltration. The disease 
widely most associated with TgAb and TPOAb is autoimmune thyroiditis, or 
Hashimoto's disease. Both TgAb and TPOAb are found in almost 100% of 
such patients. Antibodies to Tg and TPO are also detectable in 50% to 90% of 
patients with Graves' disease. 
 
Thyroid Autoantibodies in Nonautoimmune Thyroid Disorders 
Antibodies to Tg and TPO are more common in patients with sporadic goiter, 
multinodular goiter, and isolated thyroid nodules and cancer and in other 
autoimmune diseases, particularly insulin-dependent diabetes mellitus 
(IDDM). 
 
 24
Radioiodine Uptake 
Several factors make this test less frequently used than in the past. The first is 
the improvement in indirect methods for assessing thyroid status. The second 
is the decrease in normal values for thyroid RAIU consequent to the 
widespread increase in daily dietary iodine intake. 34 
 131I (half-life 8.1 days) and 123I (half-life 0.55 day) both emit gamma 
radiation, which permits their external detection and quantitation at sites of 
accumulation, such as the thyroid. 
Measurements of RAIU are generally made at 24 hours. The RAIU usually 
indicates the rate of thyroid hormone synthesis and the rate of thyroid 
hormone release into the blood. 
States Associated with Increased RAIU 
Hyperthyroidism, aberrant hormone synthesis, abnormal thyroglobulin 
synthesis, iodine deficiency, rebound increases in RAIU are seen after 
withdrawal of antithyroid therapy, after subsidence of transient or subacute 
thyroiditis, excessive hormone losses as in nephrotic syndrome and chronic 
diarrheal states. 
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States Associated with Decreased RAIU.  
Exogenous thyroid hormone(thyrotoxicosis factitia), disorders of hormone 
storage,the early phase of subacute thyroiditis and in chronic thyroiditis with 
transient hyperthyroidism, exposure to excessive iodine. 
 
HYPOTHYROIDISM 
CLINICAL PRESENTATION 
Hypothyroidism can affect all organ systems. The term myxedema, formerly 
used as a synonym for hypothyroidism, refers to the appearance of the skin 
and subcutaneous tissues in the patient in a severely hypothyroid state. 
Skin and Appendages 
Hypothyroidism causes an accumulation of hyaluronic acid in the dermis and 
other tissues. 35 Myxedematous tissue is characteristically boggy and non 
pitting and is apparent around the eyes, on the dorsa of the hands and feet, and 
in the supraclavicular fossae. The skin is pale and cool as a result of 
cutaneous vasoconstriction. The secretions of the sweat glands and sebaceous 
glands are reduced, leading to dryness and coarseness of the skin. 
Cardiovascular System 
The cardiac output at rest is decreased because of reduction in both stroke 
volume and heart rate, reflecting loss of the inotropic and chronotropic effects 
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of thyroid hormones. Peripheral vascular resistance at rest is increased, and 
blood volume is reduced. 12 36 37 38 
In severe primary hypothyroidism the cardiac silhouette is enlarged, and the 
heart sounds are diminished in intensity.39 These findings are the result largely 
of effusion into the pericardial sac of fluid rich in protein and 
glycosaminoglycans. 
Electrocardiographic changes include sinus bradycardia, prolongation of the 
PR interval, low amplitude of the P wave and QRS complex, alterations of the 
ST segment, and flattened or inverted T waves. Pericardial effusion is 
probably responsible for the low amplitude in severe hypothyroidism. 
Systolic time intervals are altered; the preejection period is prolonged, and the 
ratio of preejection period to left ventricular ejection time is increased. 
Echocardiographic studies have revealed resting left ventricular diastolic 
dysfunction in overt, and in some studies, subclinical hypothyroidism.38 The 
combination of large heart, hemodynamic and electrocardiographic 
alterations, and the serum enzyme changes has been termed myxedema heart 
Hypothyroidism has been shown to be a risk factor for atherosclerosis and 
cardiovascular disease by several studies, although others have not shown this 
association. 
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Respiratory System  
Pleural effusion is usually evident only in radiological examination.Lung 
volumes are usually normal, but maximal breathing capacity and diffusing 
capacity are reduced. Obstructive sleep apnea is common but is reversible 
with restoration of a euthyroid state. 
Alimentary System  
Although most patients experience a modest gain in weight, appetite is 
usually reduced. Peristaltic activity is decreased and together with the 
decreased food intake, is responsible for  constipation. The latter may lead to 
fecal impaction (myxedema megacolon). Gaseous distention of the abdomen 
(myxedema ileus), if accompanied by colicky pain and vomiting, may mimic 
mechanical ileus. 41 
Central and Peripheral Nervous Systems 
All intellectual functions, including speech, are slowed. Dementia is seen in 
elderly patients. Psychiatric disorders are common and are usually of the 
paranoid or depressive type and may induce agitation (myxedema madness).42 
The tendon reflexes are slow, especially during the relaxation phase and is 
due to a decrease in the rate of muscle contraction and relaxation. 
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Skeletal System: Calcium and Phosphorus Metabolism 
Deficiency of thyroid hormone in early life leads to both a delay in the 
development of, and an abnormal, stippled appearance of the epiphyseal 
centers of ossification (epiphyseal dysgenesis). Impairment of linear growth 
leads to dwarfism in which the limbs are disproportionately short in relation 
to the trunk but cartilage growth is unaffected.  
Renal Function 
Renal blood flow, glomerular filtration rate, and tubular reabsorptive and 
secretory maxima are reduced. Blood urea nitrogen and serum creatinine 
levels are normal, but uric acid levels may be increased. There is impaired 
renal excretion of water and the retention of water by the hydrophilic deposits 
in the tissues result in an increase in total body water, even though plasma 
volume is reduced. 
Hematopoietic System 
In response to the diminished oxygen requirements and decreased production 
of erythropoietin, the red blood cell mass is decreased; this is evident in the 
mild normocytic, normochromic anemia that often occurs.  
Reproductive Function 
In adult women, severe hypothyroidism may be associated with diminished 
libido and failure of ovulation. Secretion of progesterone is inadequate, and 
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endometrial proliferation persists, resulting in excessive and irregular 
breakthrough menstrual bleeding.  
Hypothyroidism in men may cause diminished libido, impotence, and 
oligospermia. 
Energy Metabolism: Protein, Carbohydrate, and Lipid Metabolism 
Both the synthesis and the degradation of protein are decreased. The 
decrease in protein synthesis is reflected in retardation of both skeletal and 
soft tissue growth. 
Hypothyroidism is associated with a reduction in glucose disposal to skeletal 
muscle and adipose tissue.43 Hypothyroidism is also, however, associated 
with reduced gluconeogenesis.43 The net effect of these influences is usually a 
minimal effect of hypothyroidism on serum glucose levels. Degradation of 
insulin is slowed and the sensitivity to exogenous insulin may be increased.  
An elevation in serum LDL cholesterol has been associated, in most studies, 
with overt and subclinical hypothyroidism.40 According to most studies, 
serum HDL and triglycerides levels, are not influenced by  
hypothyroidism.40,44 
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CLASSIFICATION OF HYPOTHYROIDISM  
Acquired  
Hashimoto's thyroiditis  
Iodine deficiency (endemic goiter)  
Drugs blocking synthesis or release of T4 (e.g., lithium, ethionamide, 
sulfonamides, iodide)  
Goitrogens in foodstuffs or as endemic substances or pollutants  
Thyroid infiltration (amyloidosis, hemochromatosis, sarcoidosis, Riedel's 
struma, cystinosis, scleroderma)  
Postablative due to 131I, surgery, or therapeutic irradiation for nonthyroidal 
malignancy  
Congenital  
Iodide transport or utilization defect (NIS or pendrin mutations)  
Iodotyrosine dehalogenase deficiency  
Organification disorders (TPO* deficiency or dysfunction)  
Defects in thyroglobulin synthesis or processing  
Thyroid agenesis or dysplasia  
TSH receptor* defects  
Thyroidal Gs protein abnormalities (pseudohypoparathyroidism type 1a)  
Idiopathic TSH unresponsiveness  
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Transient (Post-thyroiditis) Hypothyroidism  
Following subacute, painless, or postpartum thyroiditis  
Consumptive Hypothyroidism  
Rapid destruction of thyroid hormone due to D3 expression in large 
hemangiomas or hemangioendotheliomas  
Defects of Thyroxine to Triiodothyronine Conversion  
Selenocysteine insertion sequence–binding protein (SECIS-BP2) defect  
Drug-Induced Thyroid Destruction  
Tyrosine kinase inhibitor (sunitinib)  
Central Hypothyroidism  
Acquired  
Pituitary origin (secondary)  
Hypothalamic disorders (tertiary)  
Bexarotene (retinaid X receptor agonist)  
Dopamine and/or severe illness  
Congenital  
TSH deficiency or structural abnormality  
TSH receptor defect  
Resistance to Thyroid Hormone 
 Generalized  and “Pituitary” dominant 
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TREATMENT 
Treatment is nearly always with levothyroxine, and the proper use of this 
medication has been reviewed extensively.45 46 47 A primary advantage of 
levothyroxine therapy is that the peripheral deiodination mechanisms can 
continue to produce the amount of T3 required in tissues under the normal 
physiologic control.  
Pharmacologic and Physiologic Considerations 
Levothyroxine has a 7-day half-life; the typical dose of levothyroxine, 
approximately 1.6 to 1.8µg/kg ideal body weight per day (0.7 to 
0.8µg/pound). Because of the 7-day half-life, approximately 6 weeks is 
required before there is complete equilibration of the free T4 and the biologic 
effects of levothyroxine. Return of the serum TSH level to normal is the goal 
of levothyroxine therapy in the patient with primary hypothyroidism. 
Institution of Replacement Therapy  
The initial dose of levothyroxine prescribed depends on the degree of 
hypothyroidism and the age and general health of the patient. Patients who are 
young or middle-aged and otherwise healthy with no associated 
cardiovascular or other abnormalities and mild to moderate hypothyroidism 
(TSH concentrations 5 to 50 mU/L) can be given an initial complete 
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replacement dose of about 1.7 µg/kg of ideal body weight. The resulting 
increase in serum T4 concentration to normal requires 5 to 6 weeks, and the 
biologic effects of T3 are sufficiently delayed that these patients do not 
experience adverse effects. 
At the other extreme, the elderly patient with heart disease, particularly 
angina pectoris, without reversible coronary lesions, should be given a small 
initial dose of levothyroxine (25 µg/day), and the dosage should be increased 
in 12.5-µg increments at 2- to 3-month intervals with careful clinical and 
laboratory evaluation. The serum TSH should be evaluated 6 weeks after a 
theoretically complete replacement dose has been instituted to allow minor 
adjustments to optimize the individual dose.48 In patients with central 
hypothyroidism, serum TSH is not a reliable index of adequate replacement 
and the serum free T4 should be restored to a concentration in the upper half 
of the normal range. Such patients should also be evaluated and treated for 
glucocorticoid deficiency before institution of thyroid replacement . 
The interval between the initiation of treatment and the first evidence of 
improvement depends on the strength of dose given and the degree of the 
deficit. An early clinical response in moderate to severe hypothyroidism is a 
diuresis of 2 to 4 kg. Thereafter, pulse rate and pulse pressure increase, 
appetite improves, and constipation may disappear. Later, psychomotor 
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activity increases and the delay in the deep tendon reflex disappears. 
Hoarseness abates slowly, and changes in skin and hair do not disappear for 
several months. In individuals started on a complete replacement dose, the 
serum free T4 level should normalize after 6 weeks; a somewhat longer 
period may be necessary for serum TSH levels to return to normal, perhaps up 
to 3 months. 
Monitoring Replacement Therapy 
Monitoring the adequacy of, and compliance with, thyroid hormone therapy 
in patients with primary hypothyroidism is easily done by measurement of 
serum TSH. Based on analysis of the NHANES III reference group,2 a 
reference TSH range with an upper limit of 2.5 mU/L(The normal serum TSH 
concentration varies between 0.5 and 4.0 mU/L) has been suggested.  
After the first 6 months of therapy, the dose should be reassessed because 
restoration of euthyroidism increases the metabolic clearance of T4. A dose 
that was adequate during the early phases of therapy may not be adequate 
when the same patient is euthyroid owing to an acceleration in the clearance 
of thyroid hormone.The finding of a normal serum TSH level on an annual 
basis is adequate to ensure that the proper levothyroxine dose is being taken 
by the patient. If the serum TSH level is above the normal range and 
noncompliance is not the explanation, small adjustments, usually in 12-µg 
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increments, can be made with reassessment of TSH concentrations after the 6 
weeks required for full equilibration have passed.  
 
CONDITIONS THAT ALTER LEVOTHYROXINE  REQUIREMENTS 
Increased Levothyroxine Requirements 
Pregnancy 
Gastrointestinal Disorders  
Mucosal diseases of the small bowel (e.g., sprue), After jejunoileal bypass 
and small bowel resection, Impaired gastric acid secretion (e.g., atrophic 
gastritis). 
Therapy with Certain Pharmacologic Agents 
Drugs That Interfere with Levothyroxine Absorption 
Cholestyramine, Sucralfate, Aluminum hydroxide, Calcium carbonate, 
Ferrous sulfate. 
Drugs That Increase the Cytochrome P450 Enzyme (CYP3A4) 
Rifampin, Phenytoin, Carbamezapine, Estrogen, Sertalin 
Drugs That Block T4 to T3 Conversion  
Amiodarone 
Conditions That May Block Deiodinase Synthesis 
Selenium deficiency, Cirrhosis 
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Decreased Levothyroxine Requirements 
Aging (65 years and older),Androgen therapy in women 
 
Adverse Effects of Levothyroxine Therapy 
Excessive doses of levothyroxine causes accelerated bone loss in 
postmenopausal patient49 50 Administration of excessive doses also increases 
cardiac wall thickness and contractility and, in elderly patients, 
 increases the risk of atrial fibrillation. 36 38 
HEART DISEASE AND THYROID HORMONE THERAPY       
 Patients with coronary artery disease and primary hypothyroidism cardiac 
function is improved in response to levothyroxine therapy because of a 
decrease in peripheral vascular resistance and improvement in myocardial 
function.36 37 However, patients with preexisting angina pectoris should be 
evaluated for correctable lesions of the coronary arteries and treated 
appropriately before levothyroxine is administered. 51 52 53  
MYXEDEMA COMA 
This state, which almost invariably affects older patients and is associated 
with a high mortality rate. It is usually accompanied by a subnormal 
temperature. The external manifestations of severe myxedema, bradycardia, 
and severe hypotension are invariably present. Seizures may accompany the 
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comatose state. Factors that predispose to its development include exposure to 
cold, infection, trauma, and central nervous system depressants or anesthetics. 
Alveolar hypoventilation, leading to carbon dioxide retention and narcosis, 
and dilutional hyponatremia resembling that seen with inappropriate secretion 
of arginine vasopressin (AVP) may also contribute to the clinical state.The 
importance of the difficulty in diagnosing myxedema coma is that a delay in 
therapy worsens the prognosis. Consequently, the diagnosis should be made 
on clinical grounds, and, after sending serum for thyroid function tests, 
therapy should be initiated without awaiting the results of confirmatory tests 
because mortality may be 20% or higher. Treatment consists of administration 
of thyroid hormone and correction of  the associated physiologic 
disturbances.54 55 56  
Administration of levothyroxine as a single intravenous dose of 500 to 800µg 
serves to replete the peripheral hormone pool and may cause improvement 
within hours. Daily doses of intravenous levothyroxine, 100 µg, are given 
thereafter. Hydrocortisone (5 to 10 mg/hr) should also be given because of the 
possibility of relative adrenocortical insufficiency as the metabolic rate 
increases. Hypertonic saline and glucose may be required to alleviate severe 
dilutional hyponatremia and the occasional hypoglycemia. 
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A critical element in therapy is support of respiratory function by means of 
assisted ventilation and controlled oxygen administration. Internal warming 
by gastric perfusion may be useful. Further heat loss can be prevented with 
blankets. An increase in temperature may be seen within 24 hours in response 
to levothyroxine. Finally, the physician should assess the patient for the 
presence of coexisting disease, such as infection and cardiac or 
cerebrovascular disease. In particular, the myxedematous patient may be 
afebrile despite a significant infection. As soon as the patient is able to take 
medication by mouth, treatment with oral levothyroxine should be instituted. 
 
SUBCLINICAL HYPOTHYROIDISM 
Subclinical hypothyroidism is defined as an isolated elevated serum 
thyrotropin level in the setting of normal serum thyroid hormone levels, in the 
presence or absence of symptoms. 57   
The findings of slightly elevated TSH and normal thyroid hormone levels do 
not necessarily imply the presence of subclinical hypothyroidism. Several 
medications and conditions are known to cause an elevation in TSH. Some 
drugs such as lithium, sufonylureas, amiodarone, ethionamide, 
phenylbutazone, aminoglutethemide and iodine can interfere with thyroid 
hormone production or release and secondarily result in slight elevation of 
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TSH. In addition, dopamine antagonists such as metoclopromide and 
domperidone may cause exaggerated TSH response to TRH stimulation by 
altering the inhibitory effect of dopamine on TSH secretion. Furosemide has 
also been shown to increase levels of TSH, especially in recovering critically 
ill patients. Other conditions that cause elevated TSH include thyroid 
hormone resistance, thyroid hormone secreting tumors(both should be 
associated with high free thyroxine levels),psychiatric illness, adrenal 
insufficiency, renal failure, hyperprolactinemias  and systemic illness. 60 
PREVALENCE AND NATURAL HISTORY 
Hypothyroidism is much higher in women than men and increases with age. 
In the Whickham survey TSH levels above 6mIU/L were approximately three 
times more common in females (7.5%) than in males (2.8%) and occurred 
more frequently in females over 45 years of age . TSH levels also showed 
progressive increase with age in women but not in men. 61 
The overall prevalence have been reported to range from 4-10% in large 
population screening surveys and from 7-26% in studies of elderly. Most 
studies have shown that subclinical hypothyroidism is more frequent in 
female sex. Another study demonstrated a prevalence of elevated TSH in 16% 
men and 21% women over age of 74 years. 1, 61, 63         
 40
In patients found to have elevated TSH levels approximately 75% have values 
lower than 10mIU/L. 62  Of patients with subclinical hypothyroidism 
approximately 2%to5%  per year will progress to overt hypothyroidism. The 
rate of progression is proportional to the baseline serum TSH concentration 
and is higher in individuals with antithyroid antibodies.58 There is also a 
strong association between positive antithyroid antibodies and elevated TSH. 
Generally the prevalence of elevated TSH levels parallels that of antibody 
positivity. 61 A high prevalence of antibodies was found in a UK study where 
antibodies was present in 81% of those with TSH concentration over 
10mU/L, 46% of those with TSH over 5 mU/L and less than or equal to 
10mU/L and only in 5.7% of those whose TSH concentration was less than 
5mU/L.4 Interestingly the NHANES 111 survey found a significant 
association between anti-thyroid peroxidase antibody  with hypo- or 
hyperthyroidism but not with thyroglobulin antibody. 
After 20 years of follow up of subjects in the Whickham Survey, the risk of 
overt hypothyroidism was found to be 4.3% per year in women with elevated 
TSH and antithyroid antibodies at baseline. This is a 38 times increased risk 
over normal women. Moreover an isolated elevation in TSH or presence of 
antithyroid antibodies alone at baseline conferred an increased risk of overt 
hypothyroidism (2.6% per year and 2.1% per year respectively).58 Progression 
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to hypothyroidism was noted to be more common in those with initial TSH 
value greater than 10mU/L and in those with positive anti-thyroid antibodies.4 
Huber et al found that basal TSH , thyroid reserve( increase in T3 after TRH 
stimulation) and the presence of antimicrosomal antibodies are important 
prognostic factors in the development of overt hypothyroidism .Interestingly 
antibodies against thyroglobulin did not have a predictive value 
Effects on serum lipid levels 
Several cross sectional studies show that serum cholesterol levels are elevated 
in individuals with mild thyroid failure when compared with euthyroid 
controls.64 In other studies however the observed differences between 
euthyroid and mild hypothyroid individuals have not been significant. 65  
The Colorado study which screened 25862 subjects found that mean total 
cholesterol and low density lipoprotein cholesterol progressively increased 
with increasing TSH levels.62 A reanalysis by Tanis et al in 1996 found that 
subclinical hypothyroidism was 2 to 3 times more frequent in people with 
elevated total plasma cholesterol levels. 
Thyroid substitution therapy replacing the TSH levels to normal decreased  
total cholesterol by 0.2 to 0.4 mmol/L and mean LDL cholesterol by 0.26 
mmol/L and increased HDL cholesterol by 0.08 mmol/L while triglyceride 
and lipoprotein A1 levels remain unchanged. In another study total 
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cholesterol and LDL cholesterol level decreased only in patients with 
pretreatment TSH values >10mU/L.66 The decrease in total cholesterol and 
LDL levels with pretreatment values greater than 40mU/L was greater than 
those between 10mU/L and 40 mU/L. 
CARDIAC EFFECTS 
Cardiac changes are evident in subclinical hypothyroidism. These include 
impairment of left ventricular diastolic function at rest (affecting the 
relaxation of left ventricle and hence filling), reduced left ventricular systolic 
function, prolongation of pre- ejection time and lastly impaired intrinsic 
myocardial contractility. There is evidence that these abnormalities improve 
with levothyroxine, demonstrating that adequate thyroid replacement 
improves cardiac output accompanied by substantial decrease in systemic 
vascular resistance, a reversal of diastolic function, and importantly an 
improvement in left ventricular ejection fraction during exercise. It has been 
demonstrated in Rotterdam study that subclinical hypothyroidism is a strong 
indicator risk for atherosclerosis and myocardial infarction. 14 
Inadequately treated hypothyroidism has also been demonstrated to have 
angiographic evidence of coronary atherosclerosis progression. Impairment of 
endothelium-dependent vasodilatation, a harbinger of atherosclerosis has also 
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been detected in patients with subclinical hypothyroidism which can be 
reversed by levothyroxine supplementation. 
SOMATIC AND NEUROMUSCULAR EFFECTS 
Patients with subclinical hypothyroidism can have subtle clinical 
manifestations and non-specific symptomatlogy such as dry skin, cold 
intolerance, constipation and easy fatigability. In addition, patients with 
muscular symptoms have mitochondrial oxidative dysfunction with 
significant lactate increment during exercise. Misuna et al also demonstrated 
the presence of subclinical polyneuropathy of probable axonal orgin in 
patients with subclinical hypothyroidism. 67 
Subclinical hypothyroidism patients reported significantly more total 
symptoms than euthyroid individuals in Colarado study 62 and 
 these symptoms do improve with Levothyroxine therapy. The greatest 
improvement is seen of patients with baseline TSH of > 12 mU/L. Kong et al 
observed no improvement in symptoms score after trial of thyroxine for six 
months in patients with TSH level between 5 and 10mU/L. 67  
Prospective studies suggest that patients with mild thyroid failure have a 
higher prevalence of somatic symptoms, mood disorders, cognitive 
dysfunction, and atypical responses to standard psychiatric therapeutic 
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interventions.57 Subclinical hypothyroidism lowers the threshold of  
depression. 
TREATMENT 
Risk and benefits of treatment 
Among patients with untreated subclinical hypothyroidism there is no single 
level of serum TSH at which clinical action is always either indicated or 
contraindicated. As the serum TSH concentration increases above 10mU/L 
however, the basis for initiating treatment is more compelling. Clinical 
context is particularly important. This opinion reflects clinical experience and 
judgment as well as literature that suggest improvement in symptoms and 
possible lowering of LDL cholesterol. There are no studies that demonstrate 
decreased morbidity or mortality with treatment. The potential risk of therapy 
are limited to the development of subclinical hyperthyroidism, which may 
occur in 14% to 21% of individuals treated with levothyroxine. 
 
Subclinical hypothyroidism with serum TSH of 4.5-10mU/L 
Although some studies suggest an association between subclinical 
hypothyroidism and systemic hypothyroid symptoms62 or cardiac 
dysfunction11 others do not. The available data does not confirm clear cut 
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benefits for early therapy compared with treatment when symptoms of overt 
hypothyroidism develop. 67 
Therefore routine levothyroxine treatment for patients with TSH levels 
between 4.5 and 10 mU/L is not recommended but thyroid function tests 
should be repeated at 6-12 month intervals to monitor improvement or 
worsening in TSH level 
 
Subclinical hypothyroidism with serum TSH higher than 10 mU/L 
Levothroxine therapy is reasonable for patients with subclinical 
hypothyroidism and serum TSH  higher than 10 mU/L. The rate of 
progression is 5% in comparison with lower levels of TSH and treatment may 
potentially prevent the manifestations and consequences of hypothyroidism in 
those patients who do progress. Still, the evidence that therapy will reduce 
total and LDL cholesterol levels and improve symptoms in these patients is 
inconclusive. 
 
Subclinical hypothyroidism during pregnancy 
Pregnant women or women of child bearing potential planning to become 
pregnant who are found to have elevated TSH should be treated with 
levothyroxine to restore the serum TSH concentration to reference range . 
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This recommendation is based on the possible association between high TSH 
and either increased fetal wastage or subsequent neuropsychological 
complications occurring in the offspring due to thyroid insufficiency. 
Although there are no published intervention trials assessing the benefits of 
thyroid hormone replacement in this special population, the potential benefit- 
risk ratio of levothyroxine therapy justifies its use .It is important to note that 
the requirement for levothyroxine in treated hypothyroid women frequently 
increases in pregnancy, therefore serum TSH concentration should be 
monitored every 6 to 8 weeks during pregnancy and the levothyroxine dose 
modified as needed. The risks of appropriately managed levothyroxine 
therapy are minimal. 
Subclinical hypothyroidism in treated overt hypothyroid individuals 
When subclinical hypothyroidism is noted in levothyroxine treated patients 
with overt hypothyroidism, the dosage of levothyroxine should be adjusted to 
bring serum TSH into reference range. Whether the target TSH level should 
be in the lower half of reference range is controversial because there are no 
data demonstrating improved clinical outcomes with this strategy. 
Nevertheless , when serum TSH is in the upper half of reference range and 
levothyroxine treated patients continue to note symptoms suggestive of 
hypothyroidism, it is reasonable to increase levothyroxine dosage to bring 
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serum TSH into lower portion of reference range. The rapidity of dosage 
adjustment depends on patient’s age and medical comorbidities. Minimal 
TSH elevations may not require dosage adjustment in patients who feel well, 
particularly those with arrhythmias or other cardiac disorders. 
To conclude, the patients with TSH levels greater than 10mU/L should be 
treated with thyroxine .The AACE has recommended treatment in patients 
with TSH levels between 5 and 10 m U/L in conjunction with goiter or 
positive anti-thyroid, peroxidase antibodies or both and also in the presence of 
symptoms. If the patients are antibody negative and TSH levels are between 5 
and 10 mU/L, then an annual check of serum TSH is recommended with 
commencement of T4 once serum TSH rises above 10mU/L 
Arguments against treatment 
The arguments against treatment are its expense and the likelihood that some 
or even most patients will not benefit. There is also a danger of over 
treatment, which could cause iatrogenic hypethyroidism and ultimately lead 
to more serious abnormalities ( eg; osteopenia and atrial fibrillation) than 
leaving the subclinical hypothyroidism untreated. Indeed in one large study, 
suppressed serum TSH consistent with the occurrence of over treatment were 
found in 21 % of patients taking thyroid hormones. 
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THYROXINE THERAPY 
Given the high rate of conversion of subclinical hypothyroidism to overt 
hypothyroidism in the presence of circulating antithyroid antibodies, it makes 
sense to treat asymptomatic patients with positive antibody tests even if they 
have normal serum lipid levels. However , because an elevated serum 
thyrotropin level is associated with an increased risk of overt hypothyroidsm 
even in the absence of antithyroid antibodies, positive antithyroid antibody 
titers  should not be the sole criterion for therapy. It is also reasonable to treat 
subclinical hypothyroidism in pregnant women and women who have 
ovulatory dysfunction with infertility. 
A therapeutic trial for subclinical hypothyroidism is warranted if patients 
have symptoms consistent with the presence of mild hypothyroidism, 
hypercholesterolemia , or goiter . Although the overlap in symptoms between 
patients with subclinical hypothyroidism and euthyroid patients make it 
difficult to predict who will have response to treatment, some patients have a 
remarkable improvement in their symptoms with thyroxine therapy. The 
positive findings in some small clinical trials 3 68 also support the use of 
therapy in symptomatic patients and thyroid replacement can always be 
discontinued if there is no apparent benefit. 
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An initial dose of thyroxine of 0.05 to 0.075 mg per day is usually sufficient 
to normalize the serum TSH level. Patients with coronary artery disease 
should receive lower initial doses (eg: 0.0125 to 0.025 mg). Serum  TSH level 
should be measured 4 to 6 weeks after therapy is begun and after any change 
in dose and then annually once levels becomes stable. Without treatment only 
5% of elevated serum TSH levels will return to normal values in one year in 
older patients. 
The evidence supports the use of treatment for most patients, as long as 
therapy is monitored with the use of annual measurement of serum TSH. 
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MATERIALS AND METHODS 
Case selection 
Women above the age of 50 years attending Medical out patient clinic of 
Kilpauk Medical College and Hospital , Chennai from January 2008 to June 
2008 were studied. A sample of 100 women was randomly selected. Informed 
consent was obtained from all participants. All the participants were 
examined for thyroid function. Women with subclinical hypothyroidism 
(defined as TSH > 5.5µIU/ml with normal free T4 and free T3 ) were 
considered as cases, and women without subclinical hypothyroidism were 
considered as controls. Laboratory measurements and clinical assessment was 
carried out in all the participants. 
Exclusion criteria 
Those with  
Known thyroid disease 
History of neck irradiation 
Chronic renal failure 
Severe illness ( such as infections , recent myocardial infarctions, severe heart 
failure or recent intensive care admission) 
Taking drugs such as beta-blockers, amiodarone, interferon –α  
were excluded 
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Measurements 
Thyroid function test- Free T4, Free T3 and TSH levels were measured. 
Thyroid function test is done using the electro chemiluminence method. The 
normal range for TSH is 0.30-5.50 µIU/ml, for Free T4 the normal range is 
0.70-1.80 ng/dl, and for Free T3 it is 1.70-4.20 pg/ml. 
Clinical Assessments 
Participants were examined for the presence of goiter and symptoms of 
hypothyroidism. 
Analytical methods 
The following data were collected from the entire study group 
• Age 
• Presence of Hypertension ( defined as BP > 140/90 mm Hg on more 
than one occasion or the patient is known to be hypertensive) 
• Diabetes mellitus ( defined as fasting blood sugar >126 mg% on two 
consecutive readings one month apart or the patient is known to be 
diabetic) 
• Ischemic heart disease ( defined as angina or myocardial infarction by 
self report or by analysis of standard 12 lead ECG for ischemic heart 
disease changes ) 
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• Comparison between cases (subclinical hypothyroidism) and normal 
control subjects of similar age and ethnic group was done with regard 
to presence of IHD ,Hypertension and Diabetes mellitus 
 
Statistical Analysis 
Statistical analysis was done using the statistical package for social sciences 
(SPSS).Different statistical methods were used as appropriate.   Mean ± SD 
was determined for quantitative data and frequency for categorical variables. 
The independent t- test was performed on all continuous variables. The 
normal distribution data was checked before any t-test. The Chi-Square test 
was used to analyze group difference for categorical variables. In logistic 
regression models, age was adjusted for estimation of each or all the 
independent effects of hypertension, ischemic heart disease and diabetes 
mellitus . A p- value < 0.05 was considered significant. 
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RESULTS 
100 women above the age of 50 years who visited the medical outpatient 
clinic during the study period were studied 
23 women were found to have the criteria set for the definition of subclinical 
hypothyroidism which meant a rate of 23%. Patients with subclinical 
hypothyroidism were regarded as cases and remaining 77 patients were the 
control group. 
There were differences in the mean age distribution among cases and controls 
are shown in table 1 and fig 1 
                                      Table 1 
Age in years Patients with SH  Patients without SH 
50-59 7 36 
60-69 9 24 
70 and above 7 17 
 
There were 43 patients in the age group 50-59 of which 7 (19.44%) were 
having subclinical hypothyroidism .  
In the 60-69 age group there were 33 patients of  which 9 (27.27%) were 
having subclinical hypothyroidism. 
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In the 70 and above age group there were 24 patients of which 7 (29.17%) 
were having subclinical hypothyroidism. 
The mean TSH level in patients with subclinical hypothyroidism was 
12.11µIU/mL. For FT4 it was 1.03ng/dl and for FT3 it was 2.76pg/ml . There 
were differences in FT4, FT3, TSH distribution in cases and control as shown 
in Table 2 
                                 Table 2 
 
Mean  Patients with SH Patients without TSH 
FT3 (pg/ml) 2.76 3.01 
FT4 (ng/dl) 1.03 1.14 
TSH (µIU/ml) 12.11 3.75 
 
There were 23 patients with TSH level more than 5.5 µIU/ml, the upper level 
of normal range ( 0.30-5.5 µIU/ml). They are the subclinical hypothyroid 
patients in this study. Of those 23 patients  15(65.2%) had TSH level between 
5.5 to 10 µIU/ml. The remaining 8 (34.8%) patients had TSH levels more than 
10 µIU/ml as shown in the following Table 3 
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Table 3 
TSH levels in patients with SH 
 
Hypothyroid symptoms were reported in 7 out of 23 (30.43%) patients with 
subclincal hypothyroidism. Fatigability and constipation were the most 
common complaint, followed by weight gain .The frequency of hypothyroid 
symptoms in the subclinical hypothyroid patients are as shown in the table 4 
                                       Table 4 
Frequency of hypothyroid symptoms in patients with SH 
Fatigability 6 (26.1%) 
Constipation 6 (26.1%) 
Weight gain 4 (17.4%) 
Goiter 2 (8.7%) 
Others( cold intolerance, infertility 
etc) 
2 (8.7%) 
TSH level in µIU/ml No. of patients(%) 
Total no = 23 
5.5 – 10 15 (65.2%) 
> 10 8   ( 34.8%) 
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Goiter was present in 2 out of 23 patients with subclinical hypothyroidism 
(8.7%) and 5 out of 77 patients without subclinical hypothyroidism (6.5%). 
Other symptoms like cold intolerance infertility were present  in 2 of the 23 
patients (8.7%) with subclinical hypothyroidism and 1 of the 77 patients 
(1.3%) without subclinical hypothyroidism 
The incidence of risk factors like hypertension diabetes and ischemic heart 
disease were compared between patients with subclinical hypothyroidism and 
control. 
 They were analyzed independently with Chi-Square test. The p- value 
showed that patients with subclinical hypothyroidism were significantly 
associated with ischemic heart disease compared to controls. The  p- value is 
not significant for hypertension and diabetes. This is shown in table 5 
                                          Table 5 
 Patients with 
SH 
Patients without 
SH 
p- value 
IHD 5 (21.71%) 5   (6.5%) 0.047 
DM 4 (17.4%) 16 (20.1%) 0.490 
HT 6 (26.1%) 21 (27.3%) 0.570 
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DISCUSSION 
Sub clinical hypothyroidism is highly prevalent in elderly women. A 
prevalence of 11 – 26 % had been reported in previous studies, 4,8,23,62 our 
study shows a prevalence of 23 % in concordance with the other studies. 
Surveys that stratified TSH levels indicate a predominance of TSH < 
10µIU/ml , which accounts for about 55-85% of cases. 5,58,69 Almost 65% of 
our patients with subclinical hypothyroidism had TSH levels < 10µIU/ml. 
Studies that have reported thyroid antibody test on subjects with elevated 
TSH demonstrated seropositivity rates from 20-78%.1,4,59,70 
Several studies have suggested that mild symptoms of hypothyroidism are 
more prevalent in patients with subclinical hypothyroidism than in age 
matched controls.62,70 Fatigability and weight gain were the most frequent 
symptoms, 67 but not all studies have found his to be true.71 30% of our 
patients with subclinical hypothyroidism had symptoms of which fatigability 
(26%) and constipation (26%) were the most common 
There have been three published randomized prospective placebo controlled 
trials for the therapy of symptoms in patients with subclinical 
hypothyroidism. 21,68,72 
Two trials reported significant improvement in symptoms of hypothyroidism, 
whereas the third found no benefit of therapy. 21,68,72 The benefit of therapy 
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was related to TSH level, being more in those who have mean TSH level 
greater than or equal to 12.7µIU/ml at baseline.71 In women with SH and 
ovulatory dysfunction , thyroxine therapy may restore  fertility.73 
Case control and cross-sectional studies on association between subclinical 
hypothyroidism and cardiovascular disease have been done, but results were 
controversial.1,8,15,16,17,74 A 20 year follow up study of the original Whickham 
survey 75 showed no association between elevated TSH and increased risk of 
IHD, while a report of 1149 women from Rotterdam showed increases 
atherosclerotic vascular disease and myocardial infarction in patients with 
subclinical hypothyroidism.8 The present study showed a significant increase 
in IHD in patients with subclinical hypothyroidism compared with controls  ( 
p value of  0.047). Several studies on association between subclinical 
hypothyroidism and dyslipidemia have been done. The initial Whickham 
study observed that lipid levels were not associated with TSH elevation after 
age adjustment.1 The Colorado study and others noted a significantly elevated 
LDL cholesterol in subjects with subclinical hypothyroidism. 12,62 A report 
from Rotterdam noted that with subclinical hypothyroidism subjects actually 
had lower total cholesterol 8 
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Women with subclinical hypothyroidism did not differ from controls with 
regard to hypertension and diabetes in previous studies.8,71 The present study 
also showed it to be true. 
There is documented evidence that many ( but not all) effects are improved or 
corrected when L-thyroxine  replacement is instituted. L- thyroxine treatment 
was recommended for majority of patients with mild thyroid failure, 
particularly those with symptoms, goiter, positive thyroid antibodies and 
those who are pregnant. However, despite these positive indications that 
treatment carries some benefits, the benefits risk ratio of treatment remains to 
be determined, given the lack of outcome data and the considerable risk of 
TSH suppression in patients on L-thyroxine replacement. 
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Conclusion 
• Subclinical hypothyroidism is highly prevalent in elderly women above 
the age of 50 years 
• Most of those with subclinical hypothyroidism have TSH level below 
10µIU/ml 
• Hypothyroid symptoms are prevalent in patients with subclinical 
hypothyroidism. (30% of patients in this study) Fatigability and 
Constipation being the most common symptoms 
• Patients with subclinical hypothyroidism are more prone to develop 
ischemic heart disease 
• There is no increased risk for developing hypertension and diabetes 
mellitus in patients with subclinical hypothyroidism  
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APPENDIX 
 
1 BMI Body Mass Index 21 rT3 Reverse T3 
2 D1 Type 1 deiodinase 22 RAIU Radio Active Iodine 
Uptake 
3 D2 Type 2 deiodinase 23 RXR Retinoid X Receptor 
4 DIT Diiodothyronine 24 SH Subclinical 
Hypothyroidism 
5 DUOX Dual Oxidase 25 SLC5A Solute Carrier Family 5A 
6 E Embryonic Day 26 T3 Triiodothyronine 
7 FSH Follicle Stimulating 
Hormone 
27 T4 Tetraiodothyronine 
8 FT3I Free T3 Index 28 TBAb Thyroid Blocking 
Antibody 
9 FT4I Free T4 Index 29 TBG Thyroid Binding Globulin 
10 hCG Human chorionic 
gonadotorpin 
30 TgAb Thyroglobulin Auto 
antibody 
11 HDL High Density 
Lipoprotein 
31 THBR Thyroid Hormone Binding 
Ratio 
12 I Iodine 32 THOX Thyroid Hormone 
Oxidase 
13 IHD Ischemic Heart Disease 33 TPO Thyroid Peroxidase 
14 LDL Low Density 
Lipoprotein 
34 TPOAb Thyroid Peroxidase 
Antibody 
15 LH Luteinizing Hormone 35 TR Thyroid hormone 
Receptor 
16 MCR Metabolic Clearance 
Rate 
36 TRH Thyroid Releasing 
Hormone 
17 MCT Mono Carboxylate 
Anion Transporter  
37 TSAb Thyroid Stimulating 
Antibody 
18 MIT Mono Iodo Thyronine 38 TSH Thyroid Stimulating 
Hormone 
19 NIS Sodium Iodide 
Symporter 
39 TSHR TSH Receptor 
20 PVN Para Ventricular 
Nucleus 
40 TTR Transthyretin 
\ 
PROFORMA 
 
NAME:                                                                          IP NO: 
AGE:                                                                             ADDRESS: 
SEX:                                                                              OCCUPATION: 
HISTORY OF 
• Fatigability 
• Weight gain 
• Constipation 
• Cold tolerance 
• Other symptoms: specified 
PAST HISTORY: 
• Hypertension 
• Diabetes Mellitus 
• Coronary heart disease 
• Hypothyroidism 
• Drug intake 
• Exposure to irradiation 
• Thyroid surgery 
 
PERSONAL HISTORY 
• Menstrual history 
• Obstetric history  
CLINICAL EXAMINATION 
Pulse rate:                 Blood pressure:        Temperature:                 Goiter: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
INVESTIGATION 
• FT3, FT4, TSH 
• Fasting blood sugar 
• ECG 
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